Details of the Drug Formulations

General Information of Drug (ID: DMDYA31)

• Drug Name: Pretomanid Drug Info
• Synonyms: PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Approved	[1]
Mycobacterium infection	1B10-1B21	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 456199
  CAS Number: 187235-37-6
  TTD ID: D02AYL
  INTEDE ID: DR1338
  ACDINA ID: D01360

Full List of Drug Formulations Containing This Drug

Pretomanid 200 mg tablet

Company	Formulation ID	FDA Description
Mylan Specialty L.P.	F23264	Colloidal Silicon Dioxide; Lactose Monohydrate; Magnesium Stearate; Microcrystalline Cellulose; Povidone; Sodium Lauryl Sulfate; Sodium Starch Glycolate

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health.